Unexpectedly long persistence of anti‐SARS‐CoV‐2 spike monoclonal antibodies tixagevimab and cilgavimab in immunocompromised patients - Université Grenoble Alpes
Article Dans Une Revue Transplant Infectious Disease Année : 2023

Unexpectedly long persistence of anti‐SARS‐CoV‐2 spike monoclonal antibodies tixagevimab and cilgavimab in immunocompromised patients

Fichier non déposé

Dates et versions

hal-04559507 , version 1 (25-04-2024)

Identifiants

Citer

Quentin Perrier, Julien Lupo, Olivier Epaulard. Unexpectedly long persistence of anti‐SARS‐CoV‐2 spike monoclonal antibodies tixagevimab and cilgavimab in immunocompromised patients. Transplant Infectious Disease, 2023, 25 (6), pp.e14164. ⟨10.1111/tid.14164⟩. ⟨hal-04559507⟩

Collections

UGA LBFA
30 Consultations
0 Téléchargements

Altmetric

Partager

More